BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

938 related articles for article (PubMed ID: 16479424)

  • 1. Surveillance in Barrett's oesophagus: will a strategy focused on a high-risk group reduce mortality from oesophageal adenocarcinoma?
    Quera R; O'Sullivan K; Quigley EM
    Endoscopy; 2006 Feb; 38(2):162-9. PubMed ID: 16479424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
    Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
    Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should patients with Barrett's oesophagus be kept under surveillance? The case for.
    Armstrong D
    Best Pract Res Clin Gastroenterol; 2008; 22(4):721-39. PubMed ID: 18656826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Impact of endoscopic surveillance of Barrett's esophagus on survival of patients with esophageal adenocarcinoma].
    Incarbone R; Bonavina L; Bassi F; Peracchia A
    Chir Ital; 2002; 54(5):591-6. PubMed ID: 12469454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort.
    Dulai GS; Shekelle PG; Jensen DM; Spiegel BM; Chen J; Oh D; Kahn KL
    Am J Gastroenterol; 2005 Apr; 100(4):775-83. PubMed ID: 15784018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A surveillance programme for Barrett's oesophagus in a UK general hospital.
    Olithselvan A; Gorard DA; McIntyre AS
    Eur J Gastroenterol Hepatol; 2007 Apr; 19(4):305-9. PubMed ID: 17353694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk.
    Provenzale D; Schmitt C; Wong JB
    Am J Gastroenterol; 1999 Aug; 94(8):2043-53. PubMed ID: 10445526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer risk in Barrett's oesophagus.
    Dias Pereira A; Suspiro A; Chaves P
    Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):915-8. PubMed ID: 18049157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are screening and surveillance for Barrett's oesophagus really worthwhile?
    Sharma P; Sidorenko EI
    Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i27-32. PubMed ID: 15711005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of endoscopy surveillance for Barrett's oesophagus.
    Bright T; Schloithe A; Bull JA; Fraser RJ; Bampton P; Watson DI
    ANZ J Surg; 2009 Nov; 79(11):812-6. PubMed ID: 20078532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Barrett's esophagus: a retrospective analysis of 13 years surveillance.
    Switzer-Taylor V; Schlup M; Lübcke R; Livingstone V; Schultz M
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1362-7. PubMed ID: 18205769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of surveillance of Barrett's oesophagus on the clinical outcome of oesophageal cancer.
    Fountoulakis A; Zafirellis KD; Dolan K; Dexter SP; Martin IG; Sue-Ling HM
    Br J Surg; 2004 Aug; 91(8):997-1003. PubMed ID: 15286961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study.
    Conio M; Blanchi S; Lapertosa G; Ferraris R; Sablich R; Marchi S; D'Onofrio V; Lacchin T; Iaquinto G; Missale G; Ravelli P; Cestari R; Benedetti G; Macrì G; Fiocca R; Munizzi F; Filiberti R
    Am J Gastroenterol; 2003 Sep; 98(9):1931-9. PubMed ID: 14499768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Surveillance for Barrett's oesophagus: worthwhile?].
    Kastelein F; Kuipers EJ
    Ned Tijdschr Geneeskd; 2012; 156(49):A5497. PubMed ID: 23218039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Barrett's oesophagus: results from a 13-year surveillance programme.
    Bani-Hani K; Sue-Ling H; Johnston D; Axon AT; Martin IG
    Eur J Gastroenterol Hepatol; 2000 Jun; 12(6):649-54. PubMed ID: 10912484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Barrett's surveillance identifies patients with early esophageal adenocarcinoma.
    Wong T; Tian J; Nagar AB
    Am J Med; 2010 May; 123(5):462-7. PubMed ID: 20399324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspirin is not chemoprotective for Barrett's adenocarcinoma of the oesophagus in multicentre cohort.
    Gatenby PA; Ramus JR; Caygill CP; Winslet MC; Watson A
    Eur J Cancer Prev; 2009 Sep; 18(5):381-4. PubMed ID: 19620873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry.
    O'Connor JB; Falk GW; Richter JE
    Am J Gastroenterol; 1999 Aug; 94(8):2037-42. PubMed ID: 10445525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review article: Barrett's oesophagus and carcinoma in Japan.
    Hongo M
    Aliment Pharmacol Ther; 2004 Dec; 20 Suppl 8():50-4. PubMed ID: 15575874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience of patients undergoing photodynamic therapy for Barrett's dysplasia or cancer.
    Wolfsen HC; Hemminger LL; Wallace MB; Devault KR
    Aliment Pharmacol Ther; 2004 Nov; 20(10):1125-31. PubMed ID: 15569115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.